7-hydroxy-2-n,n-dipropylaminotetralin has been researched along with Long QT Syndrome in 1 studies
7-hydroxy-2-N,N-dipropylaminotetralin: RN given refers to cpd without isomeric designation
Long QT Syndrome: A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Torres-Jácome, J | 1 |
| Tejeda-Chávez, HR | 1 |
| Rodríguez-Menchaca, AA | 1 |
| Sánchez-Chapula, JA | 1 |
| Navarro-Polanco, RA | 1 |
1 other study available for 7-hydroxy-2-n,n-dipropylaminotetralin and Long QT Syndrome
| Article | Year |
|---|---|
The D3-dopaminergic agonist 7-hydroxy-dipropylaminotetralin (7-OH-DPAT) increases cardiac action potential duration and blocks human ether-a-go-go-related gene K+ channel.
Topics: Action Potentials; Animals; Cats; Cell Line; Dopamine Agonists; ERG1 Potassium Channel; Ether-A-Go-G | 2006 |